Pediatrix Medical Group, Inc. (MD) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$22.93
Price Target
$22.25
Target Range
$19.00 — $27.00
Analyst Rating
Hold
Forward P/E10.3x
Trailing P/E11.8x
Forward PEG—
Implied Growth+6.6%
Median Target$21.50
Analyst Spread36.0%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$19
-17.1%
Consensus
$22
-3.0%
Bull Case
$27
+17.7%
MD Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Pediatrix Medical Group, Inc. (MD) has a Wall Street consensus price target of $22.25, based on estimates from 33 covering analysts. With the stock currently trading at $22.93, this represents a potential downside of -3.0%. The company has a market capitalization of $1.90B.
Analyst price targets range from a low of $19.00 to a high of $27.00, representing a 36% spread in expectations. The median target of $21.50 aligns closely with the consensus average.
The current analyst consensus rating is Hold, with 14 analysts rating the stock as a Buy or Strong Buy,17 rating it Hold, and 2 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, MD trades at a trailing P/E of 11.8x and forward P/E of 10.3x. Analysts expect EPS to grow +6.6% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+22.3%
Avg Forward P/E13.6x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 THCTenet Healthcare Corporation | $17.0B | $194.13 | $268.00 | +38.1% | Buy | 10.9x | 32 |
 NKTRNektar Therapeutics | $1.7B | $83.37 | $132.83 | +59.3% | Buy | — | 33 |
 AMSFAMERISAFE, Inc. | $569M | $30.30 | $44.50 | +46.9% | Buy | 14.4x | 6 |
 HCAHCA Healthcare, Inc. | $95.9B | $429.17 | $527.45 | +22.9% | Buy | 14.2x | 46 |
 UHSUniversal Health Services, Inc. | $10.7B | $170.56 | $231.50 | +35.7% | Hold | 7.3x | 43 |
 CYHCommunity Health Systems, Inc. | $408M | $2.90 | $2.93 | +1.2% | Hold | — | 37 |
 ACHCAcadia Healthcare Company, Inc. | $2.3B | $24.46 | $23.50 | -3.9% | Buy | 16.4x | 25 |
 SEMSelect Medical Holdings Corporation | $2.0B | $16.44 | $18.00 | +9.5% | Hold | 13.1x | 13 |
 UNHUnitedHealth Group Incorporated | $335.6B | $369.74 | $385.43 | +4.2% | Buy | 20.2x | 52 |
 CVSCVS Health Corporation | $111.4B | $87.31 | $95.20 | +9.0% | Buy | 12.2x | 41 |
Upside Potential Comparison
NKTRAMSFTHCUHSHCASEMCVSUNHSee MD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMD — Frequently Asked Questions
Quick answers to the most common questions about buying MD stock.
What is the MD stock price target for 2026?
Wall Street's consensus price target for MD is $22.25, -3.0% from its current price of $22.93. The below-market target from 33 analysts suggests limited near-term appreciation.
Is MD a buy, sell, or hold?
MD has a consensus rating of "Hold" based on 33 Wall Street analysts. The rating breakdown is mixed, with 17 Hold ratings making up the largest segment. The consensus 12-month price target of $22.25 implies -3.0% downside from current levels.
Is MD stock overvalued or undervalued?
With a forward P/E of 10.259x, MD trades at a relatively low valuation. The consensus target of $22.25 implies -3.0% move, suggesting the market may be pricing in risks.
How high can MD stock go?
The most bullish Wall Street analyst has a price target of $27 for MD, while the most conservative target is $19. The consensus of $22.25 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover MD stock?
MD is heavily covered by Wall Street, with 33 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 14 have Buy ratings, 17 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the MD stock forecast?
The 12-month MD stock forecast based on 33 Wall Street analysts shows a consensus price target of $22.25, with estimates ranging from $19 (bear case) to $27 (bull case). The median consensus rating is "Hold".
What is MD's forward P/E ratio?
MD trades at a forward P/E ratio of 10.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 11.8x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy MD stock?
Analysts are cautious on MD, with 2 Sell ratings and a price target of $22.25 (-3.0% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do MD price targets vary so much?
MD analyst price targets range from $19 to $27, a 36% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $22.25 consensus represents the middle ground.